Press Releases

At OCTANe’s Ophthalmology Technology Summit, Bernhard Günther discusses the company’s progress in bringing eye products into the US market

11. July 2018

NOVALIQ’S NOVATEARS® TREATMENT FOR EVAPORATIVE DRY EYE DISEASE IS NOW AVAILABLE ACROSS AUSTRALIA AND NEW ZEALAND

28. June 2018

Heidelberg, Germany – June 28, 2018 – Novaliq GmbH, a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, announced that NovaTears®, a novel topical treatment of dry eye disease (DED) and meibomian gland dysfunction (MGD), is now also available in Australia. Dry eye is…

Details

Novaliq at Ophthalmology Technology Summit 2018

26. June 2018

We are delighted that Novaliq was selected as one of only four companies to present in OCTANe’s LaunchPad session during the Ophthalmology Technology Summit taking place in Newport Beach, CA on June 29, 2018. Novaliq Inc‘s president, Bernhard Günther, will present between 3:15-4:15 p.m. https://www.ots2018.com/agenda/

Study finds NovaTears increases tear film, lipid layer thickness.

5. June 2018

Gerard Garhöfer, MD, and colleagues reported in a randomized study, that NovaTears has the ability to restore the tear film over time, due to the novel mode of action – perfluorohexyloctane – preventing evaporation by stabilizing the lipid layer.

Study finds NovaTears increases tear film, lipid layer thickness

4. June 2018

Details